Clinical Trial Update: A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects [Phase 4]

View source ↗

Summary

Phase 4 trial investigating how residual inflammation, drug levels, and patient factors influence dose tapering of adalimumab in rheumatoid arthritis patients i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: AbbVie | Conditions: Rheumatoid Arthritis, Musculoskeletal and Connective Tissue Diseases | Phase 4 | Status: COMPLETED | Results posted: 2019-06-25